{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:14:12Z","timestamp":1778105652687,"version":"3.51.4"},"reference-count":0,"publisher":"Association of Basic Medical Sciences of FBIH","issue":"9","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>Real-world evidence regarding biologic therapy in geriatric psoriasis is limited, particularly concerning systemic inflammatory burden and infection-related safety. This study evaluates the clinical efficacy of biologic therapy and its impact on systemic inflammatory indices while emphasizing safety related to hepatitis B virus (HBV) serology and tuberculosis screening. We conducted a retrospective analysis of eighty biologic-na\u00efve patients aged 65 years and older with plaque psoriasis undergoing biologic therapy. Patients were categorized by biologic class: tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors, interleukin-17 inhibitors, an interleukin-12\/23 inhibitor, and interleukin-23 inhibitors.\u00a0The primary outcomes included changes in Psoriasis Area and Severity Index (PASI) scores and blood count-derived inflammatory indices over time (baseline and 6 months). Secondary outcomes encompassed changes in HBV serologic status and QuantiFERON-TB (QFT) results. Data analysis utilized longitudinal mixed-effects models for repeated measures. Blood count-derived inflammatory indices, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), were assessed at baseline and 6 months, alongside HBV serology and QFT results.\u00a0PASI scores demonstrated significant improvement over time (p\u00a0&lt;\u00a00.001), with no notable differences among biologic classes after adjusting for baseline covariates. Significant time effects were observed for all inflammatory indices (all p\u00a0&lt; 0.001), with significant group \u00d7 time interactions noted for SII and NLR (both p\u00a0&lt; 0.05). Variability in HBV serologic markers and QFT results was observed during follow-up; however, no cases of active tuberculosis or clinically overt hepatitis were identified. In conclusion, biologic therapy led to substantial clinical improvement in geriatric psoriasis, accompanied by reductions in systemic inflammatory indices over a 6-month period, without evidence of clinically overt hepatitis or active tuberculosis during follow-up.<\/jats:p>","DOI":"10.17305\/bb.2026.13927","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:42:28Z","timestamp":1772617348000},"page":"1584-1594","source":"Crossref","is-referenced-by-count":0,"title":["Biologic therapy in geriatric psoriasis: 6-month real-world data on PASI, inflammatory indices, and hepatitis B\/tuberculosis safety"],"prefix":"10.17305","volume":"26","author":[{"given":"Esranur","family":"\u00dcnal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1163-3166","authenticated-orcid":false,"given":"Beste","family":"Pak\u0131rda\u015f\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Emre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed Burak","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burak","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3945-3829","authenticated-orcid":false,"given":"Esma Nur","family":"\u00d6zbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur\u015fah","family":"Gedikli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"At\u0131l","family":"Avc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rag\u0131p","family":"Erta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-0430","authenticated-orcid":false,"given":"Orhan","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6922","published-online":{"date-parts":[[2026,3,4]]},"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/13927\/4146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/13927\/4146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:02:07Z","timestamp":1778104927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/13927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":0,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.17305\/bb.2026.13927","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}